Categories

Sign Up to Receive the Latest Trading Tips and News from Prosper



    February 7, 2019

    Look Out Below For Sangamo Therapeutics

    Sangamo Therapeutics (SGMO) shares slumped over -30% lower due to a failed Phase 1/2 study. The company reported its SB-318 genome editing product did not appear to show any clinical benefits. The company does have an extensive pipeline of treatments in clinical trials, as well as partnerships with major companies such as Pfizer. However, this […]

    Read Article